What is GLP-1? Mechanism, receptors and the clinical landscape

GLP-1 as a native hormone

Glucagon-like peptide-1 (GLP-1) is a peptide hormone produced mainly by enteroendocrine L-cells lining the distal small intestine and colon. It is one of two principal 'incretin' hormones — the other being glucose-dependent insulinotropic polypeptide (GIP) — that are released into the bloodstream within minutes of nutrient intake, well before circulating glucose itself rises substantially.

The incretin effect describes the observation, established in human physiology studies from the 1960s onward, that oral glucose provokes a much larger insulin response than an intravenous glucose infusion matched for blood glucose concentration. GLP-1 and GIP together account for the majority of this effect, which is substantially blunted in people with type 2 diabetes.

Once secreted, native GLP-1 is extremely short-lived. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it within one to two minutes, and renal clearance removes it further, giving active GLP-1 a circulating half-life measured in minutes. This is precisely why endogenous GLP-1 cannot be given as a drug — it would be degraded before it did anything useful.

How GLP-1 signalling works

GLP-1 exerts its effects through the GLP-1 receptor, a class B G-protein-coupled receptor found on pancreatic beta cells, alpha cells, neurons in the hypothalamus and brainstem, cardiac tissue, and elsewhere. Receptor activation raises intracellular cyclic AMP, which in beta cells amplifies glucose-stimulated insulin secretion.

Critically, this insulinotropic action is glucose-dependent: GLP-1 receptor activation increases insulin release when glucose is elevated but has a much smaller effect at normal or low glucose levels. This property is a key reason GLP-1-based therapies carry a comparatively low intrinsic risk of hypoglycaemia when used alone.

From native hormone to approved medicine

Because native GLP-1 is degraded almost immediately, drug developers built molecules that activate the same receptor but resist DPP-4 cleavage or clear more slowly from circulation. Exenatide, derived from a peptide found in Gila monster saliva (exendin-4), was the first GLP-1 receptor agonist approved by the FDA, in 2005, for type 2 diabetes.

Subsequent generations — liraglutide (once daily), dulaglutide and semaglutide (once weekly) — used fatty-acid acylation or fusion to albumin-binding domains to extend half-life dramatically, from roughly 13 hours for liraglutide to about a week for semaglutide and dulaglutide. Semaglutide was later approved as an oral tablet co-formulated with an absorption enhancer, the first oral peptide of its kind.

This engineering trajectory — take a fragile natural signal and make it pharmacologically durable — is the throughline for the entire incretin drug class, and it is the same logic later extended to dual and triple agonists described elsewhere on GLPWiki.

What human trials actually show

The clinical evidence base for GLP-1 receptor agonists is unusually large for a peptide drug class, spanning glycaemic control, weight management and cardiovascular outcomes across tens of thousands of randomised trial participants.

For type 2 diabetes, agents such as liraglutide, dulaglutide, exenatide and semaglutide have consistently lowered HbA1c relative to placebo and, in many head-to-head trials, relative to other glucose-lowering drug classes, while also producing modest to substantial weight loss rather than the weight gain associated with some older diabetes drugs.

For obesity specifically, the STEP trial programme for semaglutide 2.4 mg reported mean weight reductions of around 15% of body weight over 68 weeks in adults without diabetes, published in the New England Journal of Medicine. Liraglutide 3.0 mg (SCALE programme) showed smaller but still clinically meaningful reductions of roughly 5-8%.

Safety profile and tolerability

The most common adverse effects reported across GLP-1 receptor agonist trials are gastrointestinal: nausea, vomiting, diarrhoea and constipation, typically most pronounced during dose escalation and diminishing over time. Discontinuation rates due to gastrointestinal events are consistently higher than placebo across trials.

Regulatory labels for this class carry warnings regarding acute pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumours based on rodent studies, with human relevance still debated and monitored through post-marketing surveillance. People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are excluded from use per FDA labelling.

A note on terminology and unapproved products

'GLP-1' is often used loosely in public discussion to mean any drug in this general mechanistic family, including dual and triple agonists that also act on other receptors (see GLPWiki's guides on dual agonists and on so-called 'GLP-3' compounds). Precision matters: a molecule's receptor pharmacology determines its evidence base, and evidence for one compound should not be assumed to transfer to another simply because both are described informally as 'GLP-1 drugs'.

This article describes biology and published trial data. It is not medical advice, and it does not describe how to obtain, prepare or dose any substance.